Results
Results in silico
We choose our synthetases because of a good total score and a good ligand score. We checked the corresponding PDB-files, and rated the ligand and the binding pocket
as satisfying, so that the ligand assumedly does not collide with residues in the near environment.
The total scores for CBT are not as good as the scores for NPA. However, the ligand scores are acceptable in both cases. A visual evaluation confirms that the ligand
fits into the binding pocket.
Our results for this step
We used this algorithm to simulate the evolution of the tyrosyl-tRNA with the amino acids Nitrophenylalanine(NPA) and N
γ‑2‑cyanobenzothiazol‑6‑yl‑L‑asparagine (CBT-asparagine).
NPA simulation:
We created one .cst-file-block for the nitrogroup of NPA. Since there are two oxygen-atoms in the nitrogroup,
we defined two atom nametags. As several possibilities are useful, we defined two possible constraint partners
for the hydrogen bonds. The first is asparagine (N) or glutamine (Q) and the second is glycine (G). We set the
possible distance to 2.8 A, as it is the optimal distance for hydrogenbonds, and a tolerance level of 0.5 A.
We set the angles to 120° with a tolerance of 40°, as recommended by Florian Richter during our talk in cologne.
The torsion angles were set to 180° with a tolerance of 180° and a penalty of 0, such that the torsion angles can rotate
completely freely.(Richter, unpublished data)
CBT-ASP simulation:
CBT-ASP can build hydrogen bonds in two ways. The first is a weak hydrogen bond on the
sulphur atom and the other possibility is a normal hydrogen bond on the nitrogen (N2)
after the Cγ. We wrote three cst-files, one for a possible bond with sulpur, one for a
possible bond with nitrogen, and one for both bonds. As possible corresponding amino acids, we chose serine, threonine, tyrosine, asparagine, glutamine, and glycine.
It is recommended to write a “.flags”-file, because there are several input- parameters to be defined, but it is also possible to define them via console user interface.
For the categorization of the scaffold, we chose the automatic determination and set the following cuts: cut1: 6 A, cut2: 8 A, cut3: 10 A and cut4: 12 A, like the baker-lab commonly used.
We used this algrithm to simulate the evolution of the tyrosyl-tRNA with the amino acids Nitrophenylalanine and CBT-ASP
We obtained 13 synthetase sequences for CBT-ASP, and 43 sequences for NPA, which fit well into the binding site according to the ROSETTA score.
The sequences for the best synthetases for NPA is avaible
.
Sequence Number |
Total Score |
Ligand Score |
15 |
124.88 |
-3.77 |
19 |
23.55 |
-3.93 |
31 |
-3.40 |
-2.47 |
32 |
-1.57 |
-3.82 |
40 |
11.67 |
-4.33 |
41 |
11.55 |
-2.98 |
43 |
66.36 |
-5.05 |
Position |
Synthetase Number |
Original Amino Acid |
Mutation Amino Acid |
30 |
5 |
Serine |
Asparagine |
32 |
5 |
Tyrosine |
Threonine |
34 |
2, 4 |
Glycine |
Alanine |
36 |
2 |
Glutamine Acid |
Isoleucine |
61 |
5 |
Asparagine Acid |
Arginine |
63 |
5 |
Isoleucine |
Alanine |
65 |
4 |
Leucine |
Glycine |
65 |
5 |
Leucine |
Threonine |
68 |
4 |
Asparagine Acid |
Alanine |
69 |
4 |
Leucine |
Alanine |
70 |
2 |
Histidine |
Asparagine Acid |
70 |
4 |
Histidine |
Glycine |
72 |
4 |
Tyrosine |
Glutamine Acid |
73 |
2 |
Leucine |
Alanine |
73 |
4 |
Leucine |
Methionine |
74 |
2 |
Asparagine |
Asparagine Acid |
76 |
2 |
Lysine |
Serine |
79 |
4 |
Leucine |
Arginine |
101 |
5 |
Lysine |
Glutamine Acid |
103 |
5 |
Valine |
Triptophane |
104 |
5 |
Tyrosine |
Valine |
105 |
4, 5 |
Glycine |
Serine |
107 |
5 |
Glutamine Acid |
Lysine |
108 |
4 |
Phenylalanine |
Lysine |
108 |
5 |
Phenylalanine |
Arginine |
109 |
4, 5 |
Glutamine |
Alanine |
114 |
4 |
Tyrosine |
Alanine |
115 |
4 |
Threonine |
Triptophane |
118 |
4 |
Valine |
Serine |
134 |
2 |
Methionine |
Asparagine |
137 |
2 |
Isoleucine |
Alanine |
139 |
2 |
Arginine |
Serine |
147 |
2, 4 |
Alanine |
Serine |
148 |
2 |
Glutamine |
Lysine |
149 |
2 |
Valine |
Threonine |
150 |
2, 4 |
Isoleucine |
Leucine |
151 |
2 |
Tyrosine |
Serine |
152 |
2 |
Proline |
Threonine |
153 |
2 |
Isoleucine |
Leucine |
153 |
4 |
Isoleucine |
Threonine |
154 |
2 |
Methionine |
Asparagine |
154 |
4, 5 |
Methionine |
Serine |
155 |
2 |
Glutamine |
Glycine |
155 |
4, 5 |
Glutamine |
Alanine |
156 |
4 |
Valine |
Alanine |
157 |
4 |
Asparagine |
Alanine |
158 |
4, 5 |
Asparagine |
Tyrosine |
159 |
4 |
Isoleucine |
Glycine |
161 |
4 |
Tyrosine |
Glutamine Acid |
161 |
5 |
Tyrosine |
Asparagine Acid |
162 |
4 |
Leucine |
Methionine |
162 |
5 |
Leucine |
Alanine |
164 |
5 |
Valine |
Alanine |
172 |
2 |
Glutamine Acid |
Lysine |
173 |
2 |
Glutamine |
Serine |
176 |
2 |
Isoleucine |
Serine |
204-210 |
2, 4, 5 |
varying |
- |
307 |
2 |
- |
Alanine |
307 |
4, 5 |
- |
Tyrosine |
Results in vivo
In order to test the functionality and specificity of our modeled aaRS, we translated a selection of the most promising amino acid sequences into DNA sequences optimized for E.coli and ordered them via gene synthesis. We then used a positive-negative selection system for characterization. The experiment proceeds as follows:
Due to problems with regards to the protein- and salt-concentration, we retransformed the gensyntheses which had been cloned into pSB1C3. In a next step, these syntheses were cotransformed in E.coli(BL21) with our positive selection plasmid.
With regards to CBT2, only the original colony could be transformed. From CBT4 and CBT5, were used each originally isolated clone and its retransformed counterpart.
Due to the IPTC-induced promoter, we used variants without IPTG, and with 5 mM, 10 mM, and 15 mM added IPTS for all plasmids for the kanamycine resistance.
We chose additional variants with regards to the antibiotics; one variant each of kanamycine, kanamycine and chloramphenicole, and kanamycine, chloramphenicole and tetracycline. The number of resulting colonies for each variant are summarized in figure X. Our in vivo results show that our in silico designed enzymes did not lead to a loss of functioning.
We ordered seven synthetase sequences of NPA via IDT, and four synthetase sequences of CBT-Asparagine by courtesy of Genscript, where we had previously
won a grant of 500€. Due to problems on the part of IDT, the sequences for NPA could not be synthetized. We still provide the sequences for further use below.
All further descriptions therefore refer to the synthetase sequences for CBT-Asparagine.
Unfortunately, we were not able to amplify the four sequences or clone them into the detection system pSB3T5. A test digestion revealed that the length of the
sequence in the plasmid pUC57, which was the plasmid delivered by Genscript, did not correspond to the sequence length ordered. Therefore, we disregarded synthetase candidate number 1
for further tests.
For the remaining three sequences, we instead utilized the positive-negative selection plasmids for validation of our syntheses.
After the first, positive selection cycle, colonies formed only if the non-canonical amino acid was present.
Thus, through the positive selection, we could show that the synthetase did not lead to the loss of functioning of the enzyme.
To show specificity, we conducted a negative selection as well. We managed to clone the synthetases into the negative selection plasmid,
but were not able to verify this selection cycle. Therefore, further tests are needed to validate the specificity of the synthetases.